Corporate Profile

OraPharma is a specialty pharmaceutical company that develops and commercializes products that improve and maintain oral health. We are dedicated to delivering scientifically and technologically advanced products to dental professionals and their practices. Our lead product, ARESTIN^® (minocycline hydrochloride), is a locally administered antibiotic for the treatment of periodontitis that utilizes an advanced controlled-release delivery system. OraPharma is proud to have introduced this revolutionary approach to treating periodontitis and continues to take a leadership role in educating clinicians and consumers on the disease. Read more about ARESTIN^®.

Our portfolio also includes partnerships with Johnson & Johnson Healthcare Products to offer our customers the LISTERINE^® family of products, which includes LISTERINE^® Antiseptic, LISTERINE^® TotalCare™ Anti-cavity Mouthwash, and LISTERINE^® Zero™, as well as REACH^® brushes and flosses—brands with a long-standing tradition of innovation. We also partner with DePuy Spine Inc. to offer HEALOS^® Bone Graft Substitute.

Plans for Growth

OraPharma is pursuing strategies to expand our offerings by:

• Investing in additional research to better meet the needs of the field.
• Investing in global expansion of the ARESTIN^® brand, which is currently available in 6 countries
• Seeking to significantly expand our portfolio of products to provide more comprehensive solutions for our customers

In order to accomplish these goals, we will continue to build on our strong institutional knowledge and successes in the dental market, optimized by our clinically trained specialty account teams. These teams of experts are unique in the oral healthcare market and offer an unrivaled level of commitment to our customers. Learn more about what we offer prospective partners.